BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aomatsu T, Yoden A, Matsumoto K, Kimura E, Inoue K, Andoh A, Tamai H. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci. 2011;56:2372-2377. [PMID: 21394462 DOI: 10.1007/s10620-011-1633-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
Number Citing Articles
1 Salama RI, Ahmed MH. Can Fecal Calprotectin Reflect Your Colonic Status? Journal of Coloproctology. [DOI: 10.1055/s-0041-1739351] [Reference Citation Analysis]
2 Koninckx CR, Donat E, Benninga MA, Broekaert IJ, Gottrand F, Kolho KL, Lionetti P, Miele E, Orel R, Papadopoulou A, Pienar C, Schäppi MG, Wilschanski M, Thapar N. The Use of Fecal Calprotectin Testing in Paediatric Disorders: A Position Paper of the European Society for Paediatric Gastroenterology and Nutrition Gastroenterology Committee. J Pediatr Gastroenterol Nutr 2021;72:617-40. [PMID: 33716293 DOI: 10.1097/MPG.0000000000003046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jeong H, Kim IY, Bae EK, Jeon CH, Ahn KS, Cha HS. Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice. Sci Rep 2021;11:11923. [PMID: 34099783 DOI: 10.1038/s41598-021-91320-1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Yu Y, Zhao H, Luo Y, Lou J, Chen J, Fang Y. Poor Concordance Between Clinical Activity and Endoscopic Severity in Pediatric Crohn's Disease: Before and After Induction Therapy. Dig Dis Sci. 2021;. [PMID: 33818661 DOI: 10.1007/s10620-021-06917-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shentova-eneva R, Velikova T. Laboratory Assessment of Disease Activity in Pediatric Patients with Inflammatory Bowel Disease: What’s New? Gastroenterology Insights 2020;11:58-71. [DOI: 10.3390/gastroent11020009] [Reference Citation Analysis]
6 Emad Y, Ragab Y, Hammam N, El-Shaarawy N, Fawzi M, Amer A, El-Makhzangy H, Ismail A, Ibrahim O, Hassan Y, Kamal A, Rasker JJ. The Clinical Utility of Faecal Calprotectin in Patients with Differentiated and Undifferentiated Spondyloarthritis: Relevance and Clinical Implications. Reumatol Clin (Engl Ed) 2020:S1699-258X(20)30238-2. [PMID: 33234498 DOI: 10.1016/j.reuma.2020.10.002] [Reference Citation Analysis]
7 Iwańczak B, Ruczka M, Matusiewicz M, Pytrus T, Matusiewicz K, Krzesiek E. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci 2020;65:259-64. [PMID: 32361483 DOI: 10.1016/j.advms.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Laserna-Mendieta EJ, Lucendo AJ. Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. Clin Chem Lab Med 2019;57:1295-307. [PMID: 30785706 DOI: 10.1515/cclm-2018-1063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
9 Choi SY, Kang B, Choe YH. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Gut Liver 2019;13:541-8. [PMID: 30970435 DOI: 10.5009/gnl18129] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
10 Di Paola M, Rizzetto L, Stefanini I, Vitali F, Massi-Benedetti C, Tocci N, Romani L, Ramazzotti M, Lionetti P, De Filippo C, Cavalieri D. Comparative immunophenotyping of Saccharomyces cerevisiae and Candida spp. strains from Crohn's disease patients and their interactions with the gut microbiome. J Transl Autoimmun 2020;3:100036. [PMID: 32743520 DOI: 10.1016/j.jtauto.2020.100036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
11 Shentova R, Baycheva M, Hadjiiski P, Kofinova D, Yaneva P. Role of faecal calprotectin as a predictor of endoscopic activity in paediatric patients with ulcerative colitis. Gastroenterol Hepatol 2020;43:57-61. [PMID: 31733888 DOI: 10.1016/j.gastrohep.2019.08.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 D’arcangelo G, Oliva S, Dilillo A, Viola F, Civitelli F, Isoldi S, Cucchiara S, Aloi M. Predictors of Long-term Clinical and Endoscopic Remission in Children With Crohn Disease Treated With Infliximab. Journal of Pediatric Gastroenterology & Nutrition 2019;68:841-6. [DOI: 10.1097/mpg.0000000000002262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
13 Cozijnsen MA, Ben Shoham A, Kang B, Choe BH, Choe YH, Jongsma MME, Russell RK, Ruemmele FM, Escher JC, de Ridder L, Koletzko S, Martín-de-Carpi J, Hyams J, Walters T, Griffiths A, Turner D. Development and Validation of the Mucosal Inflammation Noninvasive Index For Pediatric Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:133-140.e1. [PMID: 30981008 DOI: 10.1016/j.cgh.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
14 Nakamura S, Imaeda H, Nishikawa H, Iimuro M, Matsuura M, Oka H, Oku J, Miyazaki T, Honda H, Watanabe K, Nakase H, Andoh A. Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study. Intest Res 2018;16:554-62. [PMID: 30301337 DOI: 10.5217/ir.2018.00027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
15 García Romero R, López Ubeda M, Cardiel Valiente L, Ros Arnal I. The importance of calprotectin for differentiating organic inflammatory disease and avoiding unnecessary procedures in paediatrics. Med Clin (Barc) 2018;151:231-5. [PMID: 29292106 DOI: 10.1016/j.medcli.2017.11.032] [Reference Citation Analysis]
16 Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. J Pediatr Gastroenterol Nutr 2017;64:955-61. [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
17 Giugliano FP, Strisciuglio C, Martinelli M, Andreozzi M, Cenni S, Campione S, D’armiento M, Staiano A, Miele E. Does Azathioprine induce endoscopic and histologic healing in pediatric inflammatory bowel disease? A prospective, observational study. Digestive and Liver Disease 2018;50:240-6. [DOI: 10.1016/j.dld.2017.10.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Di Berardino F, Zanetti D, Ciusani E, Caccia C, Leoni V, De Grazia U, Filipponi E, Elli L. Intestinal permeability and Ménière's disease. Am J Otolaryngol 2018;39:153-6. [PMID: 29248204 DOI: 10.1016/j.amjoto.2017.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Turner D, Levine A, Walters TD, Focht G, Otley A, López VN, Koletzko S, Baldassano R, Mack D, Hyams J. Which PCDAI Version Best Reflects Intestinal Inflammation in Pediatric Crohn’s Disease? J Pediatr Gastroenterol Nutr. 2016; Epub ahead of print. [PMID: 27050050 DOI: 10.1097/mpg.0000000000001227] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 9.5] [Reference Citation Analysis]
20 Kostas A, Siakavellas SI, Kosmidis C, Takou A, Nikou J, Maropoulos G, Vlachogiannakos J, Papatheodoridis GV, Papaconstantinou I, Bamias G. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(41): 7387-7396 [PMID: 29151692 DOI: 10.3748/wjg.v23.i41.7387] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 36] [Article Influence: 9.2] [Reference Citation Analysis]
21 Koutroumpakis E, Katsanos KH. Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol 2016;22:183-91. [PMID: 27184635 DOI: 10.4103/1319-3767.182455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
22 Dillman JR, Dehkordy SF, Smith EA, DiPietro MA, Sanchez R, DeMatos-Maillard V, Adler J, Zhang B, Trout AT. Defining the ultrasound longitudinal natural history of newly diagnosed pediatric small bowel Crohn disease treated with infliximab and infliximab-azathioprine combination therapy. Pediatr Radiol 2017;47:924-34. [PMID: 28421251 DOI: 10.1007/s00247-017-3848-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ministro P, Martins D. Fecal biomarkers in inflammatory bowel disease: how, when and why? Expert Rev Gastroenterol Hepatol 2017;11:317-28. [PMID: 28276813 DOI: 10.1080/17474124.2017.1292128] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
24 Kapoor A, Bhatia V, Sibal A. Pediatric inflammatory bowel disease. Indian Pediatr 2016;53:993-1002. [DOI: 10.1007/s13312-016-0975-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
25 Pieczarkowski S, Kowalska-Duplaga K, Kwinta P, Tomasik P, Wędrychowicz A, Fyderek K. Diagnostic Value of Fecal Calprotectin (S100 A8/A9) Test in Children with Chronic Abdominal Pain. Gastroenterol Res Pract 2016;2016:8089217. [PMID: 27974886 DOI: 10.1155/2016/8089217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
26 Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C, Cimaz R. Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status. Front Microbiol. 2016;7:1703. [PMID: 27833598 DOI: 10.3389/fmicb.2016.01703] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
27 Hoekman DR, Diederen K, Koot BG, Tabbers MM, Kindermann A, Benninga MA. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease. Eur J Pediatr 2016;175:1335-42. [PMID: 27573259 DOI: 10.1007/s00431-016-2762-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
28 Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Pindo M, Renzi D, Rizzetto L, Stefanini I, Calabrò A, De Filippo C. Altered gut microbiota in Rett syndrome. Microbiome 2016;4:41. [PMID: 27473171 DOI: 10.1186/s40168-016-0185-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 9.7] [Reference Citation Analysis]
29 Herrera OR, Christensen ML, Helms RA. Calprotectin: Clinical Applications in Pediatrics. J Pediatr Pharmacol Ther 2016;21:308-21. [PMID: 27713670 DOI: 10.5863/1551-6776-21.4.308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
30 McFarlane M, Chambers S, Malik A, Lee B, Sung E, Nwokolo C, Waugh N, Arasaradnam R. Clinical outcomes at 12 months and risk of inflammatory bowel disease in patients with an intermediate raised fecal calprotectin: a 'real-world' view. BMJ Open 2016;6:e011041. [PMID: 27266773 DOI: 10.1136/bmjopen-2016-011041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
31 Li Z, Long Y, Bai M, Li J, Feng Z. Neutrophil and eosinophil granule proteins as potential biomarkers of assessing disease activity and severity in patients with ulcerative colitis. J Clin Lab Anal. 2016;30:776-778. [PMID: 27076259 DOI: 10.1002/jcla.21937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Zhu Q, Li F, Wang J, Shen L, Sheng X. Fecal Calprotectin in Healthy Children Aged 1-4 Years. PLoS One 2016;11:e0150725. [PMID: 26950440 DOI: 10.1371/journal.pone.0150725] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
33 Apostolova P, Zeiser R. The role of danger signals and ectonucleotidases in acute graft-versus-host disease. Hum Immunol. 2016;77:1037-1047. [PMID: 26902992 DOI: 10.1016/j.humimm.2016.02.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
34 Radillo O, Pascolo L, Martelossi S, Dal Bo S, Ventura A. Fecal Calprotectin: Diagnostic Accuracy of the Immunochromatographic CalFast Assay in a Pediatric Population. J Clin Lab Anal 2016;30:500-5. [PMID: 26879689 DOI: 10.1002/jcla.21886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
35 Zubin G, Peter L. Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin. Inflamm Bowel Dis 2015;21:1386-91. [PMID: 25851564 DOI: 10.1097/MIB.0000000000000388] [Cited by in Crossref: 7] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
36 Cikot M, Peker KD, Bozkurt MA, Kocatas A, Kones O, Binboga S, Gedikbasi A, Alis H. Plasma calprotectin level: usage in distinction of uncomplicated from complicated acute appendicitis. World J Emerg Surg 2016;11:7. [PMID: 26819626 DOI: 10.1186/s13017-016-0062-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
37 Hiraoka S, Kato J, Nakarai A, Takashima S, Inokuchi T, Takei D, Sugihara Y, Takahara M, Harada K, Okada H. Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse. ECCOJC 2016;10:687-94. [DOI: 10.1093/ecco-jcc/jjw025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
38 Christensen B, Rubin DT. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-015-0477-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
39 Lin WC, Wong JM, Tung CC, Lin CP, Chou JW, Wang HY, Shieh MJ, Chang CH, Liu HH, Wei SC, Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol 2015; 21(48): 13566-13573 [PMID: 26730169 DOI: 10.3748/wjg.v21.i48.13566] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
40 Dolinšek J, Rižnik P, Sabath L, Mičetić-turk D. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease. Wien Klin Wochenschr 2016;128:253-9. [DOI: 10.1007/s00508-015-0915-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
41 Boon GJ, Day AS, Mulder CJ, Gearry RB. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol 2015; 21(40): 11469-11480 [PMID: 26523111 DOI: 10.3748/wjg.v21.i40.11469] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
42 Roszak D, Gałęcka M, Cichy W, Szachta P. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases. Adv Med Sci 2015;60:246-52. [PMID: 25989184 DOI: 10.1016/j.advms.2015.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
43 Cikot M, Kones O, Gedikbası A, Kocatas A, Karabulut M, Temizgonul KB, Alis H. The marker C-reactive protein is helpful in monitoring the integrity of anastomosis: plasma calprotectin. Am J Surg 2016;212:53-61. [PMID: 26606896 DOI: 10.1016/j.amjsurg.2015.06.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
44 Pletikosic S, Plavsic I, Hauser G, Tkalcic M. Fecal Calprotectin and serum chromogranin A as potential biomarkers of irritable bowel syndrome symptom severity. Med Hypotheses. 2015;85:339-342. [PMID: 26112162 DOI: 10.1016/j.mehy.2015.06.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
45 George CM, Oldja L, Biswas SK, Perin J, Lee GO, Ahmed S, Haque R, Sack RB, Parvin T, Azmi IJ, Bhuyian SI, Talukder KA, Faruque AG. Fecal Markers of Environmental Enteropathy are Associated with Animal Exposure and Caregiver Hygiene in Bangladesh. Am J Trop Med Hyg 2015;93:269-75. [PMID: 26055734 DOI: 10.4269/ajtmh.14-0694] [Cited by in Crossref: 69] [Cited by in F6Publishing: 74] [Article Influence: 9.9] [Reference Citation Analysis]
46 Visca A, Bishop CT, Hilton S, Hudson VM. Oral Reduced L-Glutathione Improves Growth in Pediatric Cystic Fibrosis Patients. Journal of Pediatric Gastroenterology & Nutrition 2015;60:802-10. [DOI: 10.1097/mpg.0000000000000738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
47 George CM, Oldja L, Biswas S, Perin J, Lee GO, Kosek M, Sack RB, Ahmed S, Haque R, Parvin T, Azmi IJ, Bhuyian SI, Talukder KA, Mohammad S, Faruque AG. Geophagy is associated with environmental enteropathy and stunting in children in rural Bangladesh. Am J Trop Med Hyg 2015;92:1117-24. [PMID: 25918214 DOI: 10.4269/ajtmh.14-0672] [Cited by in Crossref: 81] [Cited by in F6Publishing: 87] [Article Influence: 11.6] [Reference Citation Analysis]
48 Stawczyk-Eder K, Eder P, Lykowska-Szuber L, Krela-Kazmierczak I, Klimczak K, Szymczak A, Szachta P, Katulska K, Linke K. Is faecal calprotectin equally useful in all Crohn’s disease locations? A prospective, comparative study. Arch Med Sci. 2015;11:353-361. [PMID: 25995752 DOI: 10.5114/aoms.2014.43672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
49 Inoue K, Aomatsu T, Yoden A, Okuhira T, Kaji E, Tamai H. Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2014;29:1406-1412. [PMID: 24635100 DOI: 10.1111/jgh.12578] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
50 Wernimont S, Northington R, Kullen MJ, Yao M, Bettler J. Effect of an α-lactalbumin-enriched infant formula supplemented with oligofructose on fecal microbiota, stool characteristics, and hydration status: a randomized, double-blind, controlled trial. Clin Pediatr (Phila) 2015;54:359-70. [PMID: 25297064 DOI: 10.1177/0009922814553433] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
51 de Meij TG, de Boer NK, Benninga MA, Lentferink YE, de Groot EF, van de Velde ME, van Bodegraven AA, van der Schee MP. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: Proof of principle study. J Crohns Colitis. 2014;Epub ahead of print. [PMID: 25248313 DOI: 10.1016/j.crohns.2014.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
52 Prell C, Nagel D, Freudenberg F, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study. BMJ Open. 2014;4:e004558. [PMID: 24793248 DOI: 10.1136/bmjopen-2013-004558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
53 Navas-López VM, Blasco-Alonso J, Lacasa Maseri S, Girón Fernández-Crehuet F, Serrano Nieto MJ, Vicioso Recio MI, Sierra Salinas C. [Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn’s disease in the era of biologics]. An Pediatr (Barc). 2014;Epub ahead of print. [PMID: 24704330 DOI: 10.1016/j.anpedi.2014.02.027] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
54 Dhaliwal A, Zeino Z, Tomkins C, Cheung M, Nwokolo C, Smith S, Harmston C, Arasaradnam RP. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6:14-19. [PMID: 25580205 DOI: 10.1136/flgastro-2013-100420] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 7.5] [Reference Citation Analysis]
55 Lampinen M, Waddell A, Ahrens R, Carlson M, Hogan SP. CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis. J Leukoc Biol. 2013;94:1061-1070. [PMID: 23904440 DOI: 10.1189/jlb.1212640] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
56 Chiusolo P, Giammarco S, Fanali C, Bellesi S, Metafuni E, Sica S, Iavarone F, Cabras T, Messana I, Leone G, Castagnola M. Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2013;19:888-92. [DOI: 10.1016/j.bbmt.2013.03.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
57 Qualia CM, Bousvaros A. Advances in Pediatric IBD. Curr Pediatr Rep 2013;1:206-13. [DOI: 10.1007/s40124-013-0020-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
58 Samson CM, Morgan P, Williams E, Beck L, Addie-Carson R, McIntire S, Booth A, Mendez E, Luzader C, Tomer G. Improved outcomes with quality improvement interventions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2012;55:679-688. [PMID: 22699837 DOI: 10.1097/mpg.0b013e318262de16] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
59 Waddell A, Ahrens R, Tsai YT, Sherrill JD, Denson LA, Steinbrecher KA, Hogan SP. Intestinal CCL11 and eosinophilic inflammation is regulated by myeloid cell-specific RelA/p65 in mice. J Immunol 2013;190:4773-85. [PMID: 23562811 DOI: 10.4049/jimmunol.1200057] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
60 Kolho KL, Turner D. Fecal calprotectin and clinical disease activity in pediatric ulcerative colitis. ISRN Gastroenterol 2013;2013:179024. [PMID: 23533791 DOI: 10.1155/2013/179024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
61 Caccaro R, D'Incà R, Pathak S, Sturniolo GC. Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature? Expert Rev Clin Immunol 2012;8:579-85. [PMID: 22992152 DOI: 10.1586/eci.12.50] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
62 Kostakis ID, Cholidou KG, Vaiopoulos AG, Vlachos IS, Perrea D, Vaos G. Fecal calprotectin in pediatric inflammatory bowel disease: A systematic review. Dig Dis Sci. 2013;58:309-319. [PMID: 22899243 DOI: 10.1007/s10620-012-2347-5] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
63 Andoh A, Kuzuoka H, Tsujikawa T, Nakamura S, Hirai F, Suzuki Y, Matsui T, Fujiyama Y, Matsumoto T. Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn’s disease. J Gastroenterol. 2012;47:1298-1307. [PMID: 22576027 DOI: 10.1007/s00535-012-0605-0] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 11.5] [Reference Citation Analysis]